Outcomes of CAG regimen for refractory biphenotypic acute leukemia patients / 中国医学科学杂志(英文版)

ABSTRACT

<p><b>OBJECTIVE</b>To evaluated the efficiency of low-dose cytosine arabinoside plus aclarubicin with concurrent administration of granulocyte colony-stimulating factor (CAG) regimen for refractory biphenotypic acute leukemia (BAL).</p><p><b>METHODS</b>We treated 5 refractory BAL patients by CAG regimen (10 mg x m(-2) cytosine arabinoside subcutaneously administrated every 12 hours, day 1-14; 5-7 mg x m(-2) aclarubicin intravenously administrated daily, day 1-8; and concurrently used 200 microg x m(-2) x d(-1) granulocyte colony-stimulating factor subcutaneously) from November 2002 to April 2007. The efficacy of the regimen was evaluated by response rate, and the side effects were also measured.</p><p><b>RESULTS</b>The complete remission rate was 80%, median duration of absolute neutrophil count < 5.0 x 10(8)/L and platelet count < 2.0 x 10(10)/L was day 13 and day 1, respectively; and the infection rate was low (III-IV infection rate, 20.00%).</p><p><b>CONCLUSION</b>CAG regimen as remission induction chemotherapy for BAL patients is effective with a high remission rate and low toxicity.</p>